Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients
Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care
HOUSTON, March 07, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus' or the 'Company'), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the publication of results in a peer-reviewed manuscript titled, "Treatment of Recurrent Glioma by Rhenium (186Re) Obisbemeda (186RNL): a Phase 1 clinical trial" in the peer-reviewed medical journal Nature Communications.
'Peer-reviewed publication of our Phase 1 glioma data in a prestigious, high-impact factor journal is substantial validation for this important clinical program,' said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. 'Based largely on this data, our ReSPECT-GBM Phase 2 trial is currently enrolling patients at leading medical centers, bringing us closer to delivering a much-needed treatment option for this devastating disease.'
Key highlights from the publication:
Twenty-one patients were treated with doses up to 22.3 mCi of Rhenium (186Re) Obisbemeda
No dose-limiting toxicity was observed, and most adverse events were unrelated to the study treatment
Median overall survival (OS) was 11 months, surpassing the standard of care for recurrent glioblastoma, which is approximately 8 months
Median OS was strongly correlated with radiation absorbed dose to the tumor and the percentage of tumor treated
Patients receiving >100 Gy (n=12) had a median OS of 17 months, compared to 6 months for those receiving <100 Gy (n=9) (p=0.001)
Absorbed radiation doses to the tumor were as high as 739.5 Gy and were delivered without significant toxicity, exceeding levels achievable with external beam radiation therapy
The full manuscript can be accessed here.
The ReSPECT-GBM trial is actively enrolling patients; additional information about the ReSPECT-GBM trial can be found here.
About Recurrent Glioblastoma (GBM)
GBM affects approximately 15,000 patients annually in the U.S. and is the most common and lethal form of brain cancer. The average life expectancy with GBM is less than 24 months, with a one-year survival rate of 40% and a five-year survival rate of around 5%. There is no clear standard of care for recurrent GBM and the few currently approved treatments provide only marginal survival benefit and are associated with significant side effects, which limit dosing and prolonged use. Approximately 90% of patients experience GBM tumor recurrence at or near the original tumor location, yet there are no FDA-approved treatments in the recurrent or progressive setting that can significantly extend a patient's life.
About Rhenium (186Re) Obisbemeda
Rhenium (186Re) Obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) Obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) Obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
About Convection-Enhanced Delivery
Convection Enhanced Delivery (CED) is a therapeutic strategy that was developed to facilitate targeted delivery of pharmaceuticals to the brain. The CED procedure involves a minimally invasive surgical exposure of the brain, followed by placement of small diameter catheters directly into the brain tumor.
About Plus TherapeuticsPlus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking StatementsThis presentation contains statements that may be deemed 'forward-looking statements' within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as 'potential,' 'anticipating,' 'planning' and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of Rhenium (186Re) Obisbemeda including the ability of Rhenium (186Re) Obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company's future performance including the next steps in developing the Company's current assets; the Company's clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC, clinical trials; possible negative effects of Rhenium (186Re) Obisbemeda; the continued evaluation of Rhenium (186Re) Obisbemeda including through evaluations in additional patient cohorts; the intended functions of the Company's platform and expected benefits from such functions; and the development, utility and potential of the CNSide leptomeningeal metastases diagnostic test.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company's product candidates and therapies, the results of the Company's research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's liquidity and capital resources and its ability to raise additional cash, the outcome of the Company's partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company's operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics' business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics' annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC's website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor ContactCharles Y. Huang, MBADirector of Capital Markets and Investor RelationsOffice: (202)-209-5751 | Direct (301)-728-7222chuang@plustherapeutics.comSign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
$16.5M Storm Water Revenue Bond secured by the city of Norfolk
NORFOLK, Va. (WAVY) – The City of Norfolk issued a $16.5 million Storm Water Revenue Bond through the Virginia Clean Water Revolving Loan Fund on May 29, which is designed to fund storm water infrastructure improvements across Norfolk. The various projects include enhancements to St. Paul's Blue-Greenway and restoration of shorelines and wetlands across the city. The total cost of the project is expected to reach nearly $18.5 million, but the city is receiving nearly $2 million in principal forgiveness. This means the remaining balance will come at no extra cost to Norfolk. For more information on the project visit the link . Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
36 minutes ago
- Yahoo
‘Third-best season ever': Over 6.5 million skiers visited Utah's resorts during the season
SALT LAKE CITY () — 'Greatest snow on Earth,' Utah's long-running slogan, is proving itself true after another successful season at Utah's ski resorts. According to Ski Utah, this last season was the third-best in state history. There are 15 ski resorts across Utah, and together they recorded 6,503,635 visitors during the 2024-25 season, which has just wrapped up. According to a press release from Ski Utah, this is the third-highest number of skier visits in state history. This season's skier visits were down 3.6% from last year, the press release says, but the more than 6.5 million visitors this year show a 3.3% increase over Utah's five-year average. Utah's economy benefits greatly from recreation at the ski resorts. Ski Utah's president and CEO, Nathan Rafferty, emphasized skiing's impact on Utah. EXCLUSIVE: Utah man who underwent 120 surgeries advocates for rare disease awareness in Washington, D.C. 'To hit our third-best season ever and generate $2.51 billion for Utah's economy is a major win,' Rafferty is quoted in the release. 'The ski industry in Utah supports approximately 25,000 jobs, and with the 2034 Olympic and Paralympic Winter Games on the horizon, the eyes of the world will be on us once again. We're excited about the opportunities ahead and grateful to all who helped make this season a success.' Ski Utah says that ski resorts are already hard at work to prepare for the upcoming 2034 Winter Olympics. In the next two years alone, 13 new lifts are expected to finish construction and open, and many resorts are planning upgrades to their mountain areas. 'Utah's future as a global winter destination remains as promising as ever,' Ski Utah concluded. Arizona man drowns along San Juan River in Glen Canyon National Recreation Area Charges for trespassing on border military zones 'not going away' Former Utah Supreme Court Chief Justice Gordon Hall dies at 98 Two women charged with felonies after late-night assault in Logan, charges say Death penalty expert weighs in on Menzies competency ruling and appeal Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
36 minutes ago
- Yahoo
Cramer: GOP has no ‘stomach' for Medicare changes in Trump megabill
Senate Republicans appear less likely to try to make changes to Medicare Advantage as part of their massive tax and spending bill, Sen. Kevin Cramer (R-N.D.) said Wednesday. Cramer raised the idea of targeting Medicare Advantage for additional savings last week after a closed-door caucus meeting, saying the program is ideal for reform because it is rife with waste, fraud and abuse. The House-passed bill would cut more than $800 billion from Medicaid and the Children's Health Insurance Program, but some GOP lawmakers argue that other mandatory spending programs, such as Medicare, should also be reviewed for 'waste' to further reduce the cost of the bill. But Medicare has long been considered a political third rail, and Cramer on Wednesday said he doesn't think Republicans want to try to go near it — even though Medicare Advantage changes have bipartisan support. 'I don't think there's a stomach for it. I think that the president doesn't want to touch Medicare,' Cramer said. When Republicans first floated the idea of Medicare changes last week, Senate Democrats jumped to open a new line of attack. Politically, it didn't matter that Republicans were discussing bipartisan legislation sponsored by Sens. Bill Cassidy (R-La.) and Jeff Merkley (D-Ore.) that would save billions of dollars by reducing overpayments to private Medicare Advantage plans. The legislation would crack down on a practice called 'upcoding' through which insurers classify patients as sicker so the government will reimburse them at a higher rate. Cramer noted it's difficult for members to try to talk about the changes. 'To be honest, I'm the only one I know that talks about it,' Cramer said. 'I just don't know how we get to where we want to get without going after some of the bigger drivers of the debt and deficit.' Senate Republicans will be briefed by Senate Finance Committee Chair Mike Crapo (R-Idaho) on Wednesday afternoon, ahead of the release of legislative text. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.